<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01826032</url>
  </required_header>
  <id_info>
    <org_study_id>OSA-E1</org_study_id>
    <nct_id>NCT01826032</nct_id>
  </id_info>
  <brief_title>Obstructive Sleep Apneas in Elderly:Neuroimaging Changes and Neurocognitive Function Before and After Treatment</brief_title>
  <official_title>Obstructive Sleep Apneas in Elderly:Neuroimaging Changes and Neurocognitive Function Before and After Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Clinic of Barcelona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Clinic of Barcelona</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the near future more than 20% of the European population will be over 65 years old and the&#xD;
      prevalence of obstructive sleep apnea (OSA) in this aged population is known to be higher&#xD;
      than 50%. OSA is a risk factor for cognitive dysfunction in middle-aged subjects, but the&#xD;
      relationship between cognitive impairment and sleep breathing disorders (SBD) in the elderly&#xD;
      has scarcely been observed.&#xD;
&#xD;
      The aim of this study is to investigate cognitive performance in elderly OSA patients, the&#xD;
      corresponding brain morphology changes and biological markers and their reversibility with&#xD;
      continuous positive airway pressure (CPAP) treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients: We will include consecutive patients with a diagnosis of severe OSA (AHI&gt; 30)&#xD;
      without significant comorbidities or excessive daytime sleepiness (Epworth ≤ 12). Patients&#xD;
      will be randomized to CPAP treatment or conservative treatment.&#xD;
&#xD;
      Methodology: We will assess at baseline and after 3 months of treatment:&#xD;
&#xD;
        1. Neuroimaging by MRI&#xD;
&#xD;
        2. Neurocognitive function with an extensive neuropsychological battery assessing&#xD;
           principally memory, attention and executive functions (Trail-making test A and B, Rey&#xD;
           Auditory Verbal Learning Test, Digit span, Digit symbol),&#xD;
&#xD;
        3. Biological markers of inflammation and endothelial dysfunction.&#xD;
&#xD;
      Patients included in the study will be monitored and followed for three months. They will be&#xD;
      examined at the time of inclusion, after two and six weeks and at the end (12 weeks) for&#xD;
      clinical monitoring and the evaluation of adaptation to treatment and compliance.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Structural and functional brain changes</measure>
    <time_frame>at baseline and after 3 months of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of the changing of the neuropsychological tests.</measure>
    <time_frame>at baseline and after 3 months of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OSA symptoms (daytime sleepiness and everyday function) and quality of life</measure>
    <time_frame>at baseline and after 3 months of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Sleep Apnea</condition>
  <arm_group>
    <arm_group_label>CPAP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with CPAP treatment. Titration will be performed by polysomnography or automatic CPAP to determine the optimal treatment pressure.&#xD;
This group will also be instructed in hygienic-dietary measures and sleep hygiene counselling.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard care for OSA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sleep hygiene ( regular sleep schedule, avoid sedative drugs, alcohol and tobacco, physical exercise) and dietary counselling</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CPAP</intervention_name>
    <description>CPAP treatment every night plus standard care for OSA: lifestyle, and sleep hygiene counselling</description>
    <arm_group_label>CPAP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard care for OSA</intervention_name>
    <description>sleep higiene and dietary counseling</description>
    <arm_group_label>CPAP</arm_group_label>
    <arm_group_label>Standard care for OSA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Men and women ≥ 65 years old.&#xD;
&#xD;
          2. Patients diagnosed with OSA with an apnea-hypopnea index per hour &gt;30.&#xD;
&#xD;
          3. Patients with an Epworth Sleep Scale score ≤ 12 (without excessive daytime&#xD;
             sleepiness).&#xD;
&#xD;
          4. Signed written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with severe chronic diseases: cardiovascular or pulmonary, neurological&#xD;
             (stroke, epilepsy, head injury...) or psychiatric.&#xD;
&#xD;
          2. Any current significant systemic illness or unstable medical condition that could lead&#xD;
             to difficulty in complying with the protocol or may, in the opinion of the&#xD;
             investigator, compromise the conclusions.&#xD;
&#xD;
          3. Mini Mental State Exam (MMSE) &lt;24.&#xD;
&#xD;
          4. Any MRI exclusions - presence of aneurysm clips, pacemakers, mechanic heart valves,&#xD;
             ear implants, metal fragments or foreign objects in the eyes, skin or body.&#xD;
&#xD;
          5. Previous CPAP treatment.&#xD;
&#xD;
          6. Psycho-physical inability to complete questionnaires. Inadequate visual and auditory&#xD;
             acuity will be excluded.&#xD;
&#xD;
          7. Presence of any previously diagnosed sleep disorders: narcolepsy, insomnia, chronic&#xD;
             sleep deprivation, REM behavior disorder and restless leg syndrome.&#xD;
&#xD;
          8. Patients with &gt; 50% of central apneas or the presence of Cheyne-Stokes Respiration.&#xD;
&#xD;
          9. History of alcohol abuse or dependence.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Josep M Montserrat, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Spanish Research Center for Respiratory Diseases</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Clinic Barcelona</name>
      <address>
        <city>Barcelona</city>
        <state>Catalonia</state>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <study_first_submitted>March 22, 2013</study_first_submitted>
  <study_first_submitted_qc>April 3, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2013</study_first_posted>
  <last_update_submitted>January 21, 2015</last_update_submitted>
  <last_update_submitted_qc>January 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Clinic of Barcelona</investigator_affiliation>
    <investigator_full_name>Jose M. Montserrat</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

